Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096993 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
NCT00096993 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 131 participants.
The verdict
NCT00096993, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
Study Summary
This is a Phase II, randomized, placebo-controlled, double-blind, multicenter clinical trial of pertuzumab in combination with gemcitabine relative to placebo in combination with gemcitabine in subjects with advanced ovarian, primary peritoneal, or fallopian tube cancer that is resistant to platinum-based chemotherapy.
Interventions
- DRUG Placebo
- DRUG Gemcitabine
- DRUG Pertuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096993
The ClinicalTrials.gov registry entry for NCT00096993 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00096993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096993 about?
NCT00096993 is a clinical study titled "A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer". This is a Phase II, randomized, placebo-controlled, double-blind, multicenter clinical trial of pertuzumab in combination with gemcitabine relative to placebo in combination with gemcitabine in subjects with advanced ovarian, primary peritoneal, or fallopian tube cancer that is resistant to platinum...
What is the current status of trial NCT00096993?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2005-01. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00096993?
The interventions under investigation include: Placebo (DRUG), Gemcitabine (DRUG), Pertuzumab (DRUG).
Who is sponsoring clinical trial NCT00096993?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.